Physical Activity and Lymphedema (PAL) Social and Economic Quality of Life (SEQL) Study, Pennsylvania and New Jersey, 2015-2016 (ICPSR 38268)
Upper body breast-cancer related lymphedema (BCRL) is a persistent adverse outcome of cancer treatment that affects the physical health and quality of life of up to 1 in 3 of the 2.9 million breast cancer survivors in the US. For those with BCRL, known predictors of progression include BMI, type of surgery and radiation treatment, all of which are associated with social factors. This study was designed to examine the role of finances in long-term BCRL management and progression, and compare the financial experiences of patients managing BCRL to those who do not.
In 2016, the study team conducted 40 interviews with women living in Philadelphia and New Jersey, half of whom had BCRL and half who were breast cancer survivors who had not been diagnosed with BCRL. Participants were sampled from a larger longitudinal study collecting quantitative data on patient's healthcare spending over the course of a year. At the 6-month time point, 40 participants were selected randomly within strata of race, age, and socioeconomic position for 30-minute semi-structured interviews on changes in their economic situation as a result of breast cancer treatment, when applicable, both cancer treatment and ongoing BCRL management. Questions were designed to cover the ways in which costs for treatment affected the patient, their family, and their anticipated future behaviors around health or finance. Themes include interactions with insurance companies, costs of medications, and charitable support services for assisting with breast cancer and BCRL financial costs.
Expansion Research Capability to Study Comparative Effectiveness in Complex Patients, 2007-2010 [Tampa, St. Petersburg, and Clearwater, Florida] (ICPSR 34544)
Overview
The Florida Department of Health and the Florida Cancer Data System (FCDS) collaborated with a hospital network composed of nine clinical facilities, to capture electronic medical records (EMR) data of patients who were diagnosed with or treated for invasive breast cancer from 2007 to 2010. Certain hospital data elements were available throughout 2006. An additional year of 2011 follow-up data was also available for a subset of patients receiving medication treatment. The purpose of the data capture was to advance patient-centered outcomes research to reduce the morbidity and mortality of cancer and other comorbidities.
A breast cancer pilot study was also conducted from a subset of all transmitted EMR records, consisting of admission records with a principal and/or secondary ICD-9-CM diagnosis between 174.0 and 174.9. The subset dataset was then linked to the central cancer registry using patient social security number, first and last name, and date of birth. Using a deterministic matching algorithm a total of 11,506 unique patients were matched to a patient in the FCDS database, resulting in 12,804 primary tumors and 53,940 unique hospital admission records. While the hospital EMR defined the patient dataset, all registry records for that patient were included in the final breast cancer pilot database, regardless of the reporting hospital or the date of diagnosis. This was to ensure capture of the entire diagnostic and treatment profile for each breast cancer patient.
Data Access
These data are not available from ICPSR. The data contain confidential information that can directly identify a patient. There are also reporting facility data. Therefore, to obtain these data, researchers will need to follow the Florida Cancer Data System data-sharing agreement process, as outlined on the FCDS data sharing request.